Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Prati, D.    Sirchia, G.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels

Daniele Prati, MD; Emanuela Taioli, MD, PhD; Alberto Zanella, MD; Emanuela Della Torre, DSc; Sonia Butelli, DSc; Emanuela Del Vecchio, DSc; Luciana Vianello, MD; Francesco Zanuso, MD; Fulvio Mozzi, DSc; Silvano Milani, PhD; Dario Conte, MD; Massimo Colombo, MD; and Girolamo Sirchia, MD, FRCPath (Edin)

2 July 2002 | Volume 137 Issue 1 | Pages 1-10

Background: Serum alanine aminotransferase (ALT) activity, the variable most commonly measured to assess hepatic disease, fails to identify many patients with hepatic injury. Current standards for "normal" ALT level were defined by using populations that included persons with subclinical liver disease.

Objective: To update definitions of healthy ranges for serum ALT level.

Design: Retrospective cohort study.

Setting: A university hospital in Milan, Italy.

Participants: 6835 persons who were first-time blood donors from 1995 through 1999, were negative for anti–hepatitis C virus (HCV), and had no contraindications to donation and 209 persons who attempted to donate blood from 1990 through 1999 but were found to have anti–HCV antibodies. Of the latter group, 131 had HCV viremia.

Measurements: Univariate and multivariate analyses examined associations between clinical and laboratory factors and ALT levels. Healthy ranges for ALT were computed from the population at lowest risk for liver disease. Sensitivity and specificity of healthy ALT ranges were evaluated in the donors with HCV antibodies, of whom 133 had liver biopsy.

Results: Serum ALT activity was independently related to body mass index and to laboratory indicators of abnormal lipid or carbohydrate metabolism. Updated upper limits (for men, 500 nkat/L [30 U/L]; for women, 317 nkat/L [19 U/L]) were lower than current limits (for men, 667 nkat/L [40 U/L]; for women, 500 nkat/L [30 U/L]) and, during 6-month follow-up, showed superior sensitivity in identifying participants with HCV viremia (sensitivity, 76.3% [95 % CI, 69.1% to 83.6%] vs. 55% [CI, 46.4% to 63.5%]). The related tradeoff in specificity was acceptable (88.5% [CI, 79.2% to 94.6%] vs. 97.4% [91% to 99.7%]). The increased sensitivity targeted patients with minimal to mild histologic lesions.

Conclusion: In patients with chronic HCV infection or nonalcoholic fatty liver disease, revision of normal limits for ALT level is advisable.

Editors' Notes Context Current upper limits (500 nkat/L [30 U/L] for women, 667 nkat/L [40 U/L] for men) for serum alanine aminotransferase (ALT) level were defined in populations that included persons with nonalcoholic fatty liver disease (NAFLD) and persons with hepatitis C virus (HCV) infection. Contribution This study redefined ALT limits in blood donors at low risk for NAFLD and without hepatitis B or C (317 nkat/L [19 U/L] in women, 500 nkat/L [30 U/L] in men). When applied to 209 anti-HCV-positive donors, the new thresholds had 76.3% sensitivity and 88.5% specificity in identifying patients with hepatitis C viremia compared with 55% and 97.4% for old thresholds. Implications Laboratories should consider revising the upper limits of normal for ALT to improve the sensitivity of this test in identifying subclinical liver disease. –The Editors

 

Author and Article Information

From Centro Transfusionale e di Immunologia dei Trapianti, Laboratorio di Epidemiologia, Divisione di Ematologia, Istituto di Statistica Medica e Biometria, Cattedra di Gastroenterologia, and Istituto di Medicina Interna, IRCCS Ospedale Maggiore and Università degli Studi di Milano, Milan, Italy.

Grant Support: By a grant from IRCCS Ospedale Maggiore Policlinico, Milan, Italy (51501—Ricerca Corrente 1998).

Requests for Single Reprints: Daniele Prati, MD, Centro Trasfusionale e di Immunologia dei Trapianti IRCCS Ospedale Maggiore Via Francesco Sforza, 35 20122 Milano, Italy; e-mail, dprati{at}yahoo.com.

Current Author Addresses: Drs. Prati, Della Torre, Butelli, Del Vecchio, Vianello, Zanuso, Mozzi, and Sirchia: Centro Trasfusionale e di Immunologia dei Trapianti, IRCCS Ospedale Maggiore di Milano, via F.Sforza, 35, 20122 Milano, Italy.

Dr. Taioli: Laboratorio di Epidemiologia, IRCCS Ospedale Maggiore di Milano, via F.Sforza, 28, 20122 Milano, Italy.

Dr. Zanella: Divisione di Ematologia, IRCCS Ospedale Maggiore di Milano, Via F.Sforza, 35, 20122 Milano, Italy.

Dr. Milani: Istituto di Statistica Medica e Biometria, Università degli Studi, Via Venezian 1, 20133 Milano, Italy.

Dr. Conte: Cattedra di Gastroenterologia, Università degli Studi and IRCCS Ospedale Maggiore di Milano, via F.Sforza, 35, 20122 Milano, Italy.

Dr. Colombo: Istituto di Medicina Interna, Università degli Studi and IRCCS Ospedale Maggiore di Milano, via F.Sforza, 35, 20122 Milano, Italy.

Author Contributions: Conception and design: D. Prati, E. Taioli, A. Zanella.

Analysis and interpretation of the data: D. Prati, E. Taioli, L. Vianello, F. Mozzi, S. Milani, D. Conte, M. Colombo.

Drafting of the article: D. Prati, E. Taioli, A. Zanella, D. Conte.

Critical revision of the article for important intellectual content: D. Prati, E. Taioli, A. Zanella, F. Mozzi, S. Milani, D. Conte, M. Colombo, G. Sirchia.

Final approval of the article: D. Prati, E. Taioli, A. Zanella, E. Della Torre, S. Butelli, E. Del Vecchio, L. Vianello, F. Zanuso, F. Mozzi, S. Milani, D. Conte, M. Colombo, G. Sirchia.

Provision of study materials or patients: D. Prati, E. Della Torre, S. Butelli, E. Del Vecchio, L. Vianello, F. Zanuso, F. Mozzi, D. Conte, M. Colombo, G. Sirchia.

Statistical expertise: E. Taioli, S. Milani.

Obtaining of funding: D. Prati.

Administrative, technical, or logistic support: E. Della Torre, S. Butelli, E. Del Vecchio, F. Zanuso.

Collection and assembly of data: E. Della Torre, S. Butelli, E. Del Vecchio, L. Vianello, F. Zanuso, F. Mozzi.

Related articles in Annals:

Editorials
Alanine Aminotransferase Levels: What's Normal?
Marshall M. Kaplan

Annals 2002 137: 49-51. [Full Text]  

Summaries for Patients
New Definitions for Healthy Ranges of Alanine Aminotransferase, a Blood Test of Liver Function

Annals 2002 137: I-37. [Full Text]  

Letters
Healthy Ranges for Alanine Aminotransferase Levels
John R. Senior

Annals 2003 138: 156. [Full Text]  

Letters
Healthy Ranges for Alanine Aminotransferase Levels
Francesco G. De Rosa, Stefano Bonora, AND Giovanni Di Perri

Annals 2003 138: 156-157. [Full Text]  

Letters
Healthy Ranges for Alanine Aminotransferase Levels
Daniele Prati, Agostino Colli, AND Dario Conte

Annals 2003 138: 157. [Full Text]  

This article has been cited by other articles:

				E. Denney-Wilson, L. L. Hardy, T. Dobbins, A. D. Okely, and L. A. Baur Body Mass Index, Waist Circumference, and Chronic Disease Risk Factors in Australian Adolescents Arch Pediatr Adolesc Med, June 1, 2008; 162(6): 566 - 573. [Abstract] [Full Text] [PDF]

				E. S. Ford, M. B. Schulze, M. M. Bergmann, C. Thamer, H.-G. Joost, and H. Boeing Liver Enzymes and Incident Diabetes: Findings from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study Diabetes Care, June 1, 2008; 31(6): 1138 - 1143. [Abstract] [Full Text] [PDF]

				N. A. Singh and N. Reau Management of hepatitis B virus J. Antimicrob. Chemother., May 14, 2008; (2008) dkn188v1. [Abstract] [Full Text] [PDF]

				S Kechagias, A Ernersson, O Dahlqvist, P Lundberg, T Lindstrom, F H Nystrom, and for the Fast Food Study Group Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects Gut, May 1, 2008; 57(5): 649 - 654. [Abstract] [Full Text] [PDF]

				B. A. Neuschwander-Tetri, A. Unalp, M. H. Creer, and for the Nonalcoholic Steatohepatitis Clinical Rese Influence of Local Reference Populations on Upper Limits of Normal for Serum Alanine Aminotransferase Levels Arch Intern Med, March 24, 2008; 168(6): 663 - 666. [Full Text] [PDF]

				M. Lazo, E. Selvin, and J. M. Clark Brief Communication: Clinical Implications of Short-Term Variability in Liver Function Test Results Ann Intern Med, March 4, 2008; 148(5): 348 - 352. [Abstract] [Full Text] [PDF]

				G. Musso, R. Gambino, S. Bo, B. Uberti, G. Biroli, G. Pagano, and M. Cassader Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?: A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects Diabetes Care, March 1, 2008; 31(3): 562 - 568. [Abstract] [Full Text] [PDF]

				A Fraser, S Ebrahim, G Davey Smith, and D A Lawlor The associations between height components (leg and trunk length) and adult levels of liver enzymes J. Epidemiol. Community Health, January 1, 2008; 62(1): 48 - 53. [Abstract] [Full Text] [PDF]

				N. Bugeac, A. Pacht, H. Mandel, T. Iancu, A. Tamir, I. Srugo, and R. Shaoul The significance of isolated elevation of serum aminotransferases in infants and young children Arch. Dis. Child., December 1, 2007; 92(12): 1109 - 1112. [Abstract] [Full Text] [PDF]

				G. Musso, R. Gambino, F. De Michieli, G. Biroli, A. Premoli, G. Pagano, S. Bo, M. Durazzo, and M. Cassader Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake Am. J. Clinical Nutrition, September 1, 2007; 86(3): 661 - 671. [Abstract] [Full Text] [PDF]

				R. K. Schindhelm, R. J. Heine, and M. Diamant Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients: Response to Targher et al. Diabetes Care, September 1, 2007; 30(9): e94 - e94. [Full Text] [PDF]

				A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen Liver Fat in the Metabolic Syndrome J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3490 - 3497. [Abstract] [Full Text] [PDF]

				K. C. Sung, M. C. Ryan, B. S. Kim, Y. K. Cho, B. I. Kim, and G. M. Reaven Relationships Between Estimates of Adiposity, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in a Large Group of Nondiabetic Korean Adults Diabetes Care, August 1, 2007; 30(8): 2113 - 2118. [Abstract] [Full Text] [PDF]

				B. Degertekin and A. S.F. Lok When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection? Ann Intern Med, July 3, 2007; 147(1): 62 - 64. [Full Text] [PDF]

				T. Kumada, H. Toyoda, S. Kiriyama, Y. Sone, M. Tanikawa, Y. Hisanaga, A. Kanamori, J. Kondo, T. Yamauchi, and S. Nakano Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection Gut, May 1, 2007; 56(5): 738 - 739. [Full Text] [PDF]

				G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, and G. Arcaro Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients Diabetes Care, May 1, 2007; 30(5): 1212 - 1218. [Abstract] [Full Text] [PDF]

				M. C. Ryan, F. Abbasi, C. Lamendola, S. Carter, and T. L. McLaughlin Serum Alanine Aminotransferase Levels Decrease Further With Carbohydrate Than Fat Restriction in Insulin-Resistant Adults Diabetes Care, May 1, 2007; 30(5): 1075 - 1080. [Abstract] [Full Text] [PDF]

				Y. Chang, S. Ryu, E. Sung, and Y. Jang Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease Clin. Chem., April 1, 2007; 53(4): 686 - 692. [Abstract] [Full Text] [PDF]

				T. S. Burgert, S. E. Taksali, J. Dziura, T. R. Goodman, C. W. Yeckel, X. Papademetris, R. T. Constable, R. Weiss, W. V. Tamborlane, M. Savoye, et al. Alanine Aminotransferase Levels and Fatty Liver in Childhood Obesity: Associations with Insulin Resistance, Adiponectin, and Visceral Fat J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4287 - 4294. [Abstract] [Full Text] [PDF]

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				D. J. Jenkins, A. R Josse, R. Labelle, A. Marchie, L. S. Augustin, and C. W. Kendall Nonalcoholic fatty liver, nonalcoholic steatohepatitis, ectopic fat, and the glycemic index Am. J. Clinical Nutrition, July 1, 2006; 84(1): 3 - 4. [Full Text] [PDF]

				T. L. Setji, N. D. Holland, L. L. Sanders, K. C. Pereira, A. M. Diehl, and A. J. Brown Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1741 - 1747. [Abstract] [Full Text] [PDF]

				J. Marsh Making Therapeutic Decisions in Adults with Aplastic Anemia Hematology, January 1, 2006; 2006(1): 78 - 85. [Abstract] [Full Text] [PDF]

				A. J.G. Hanley, K. Williams, A. Festa, L. E. Wagenknecht, R. B. D'Agostino Jr, and S. M. Haffner Liver Markers and Development of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study Diabetes, November 1, 2005; 54(11): 3140 - 3147. [Abstract] [Full Text] [PDF]

				L. S. Szczepaniak, P. Nurenberg, D. Leonard, J. D. Browning, J. S. Reingold, S. Grundy, H. H. Hobbs, and R. L. Dobbins Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E462 - E468. [Abstract] [Full Text] [PDF]

				A. Kerner, O. Avizohar, R. Sella, P. Bartha, O. Zinder, W. Markiewicz, Y. Levy, G. J. Brook, and D. Aronson Association Between Elevated Liver Enzymes and C-Reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 193 - 197. [Abstract] [Full Text] [PDF]

				V. Cameron, K. A. Musana, S. H. Yale, and A. S. Abdulkarim Sensitivity and Specificity of Tests of Liver Injury Clin. Med. Res., November 1, 2004; 2(4): 205 - 205. [Full Text] [PDF]

				H. C. Kim, C. M. Nam, S. H. Jee, K. H. Han, D. K. Oh, and I. Suh Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study BMJ, April 24, 2004; 328(7446): 983. [Abstract] [Full Text] [PDF]

				P. Roderick Liver function tests: defining what's normal BMJ, April 24, 2004; 328(7446): 987 - 987. [Full Text] [PDF]

				R. L. Koretz Update in Gastroenterology Ann Intern Med, September 2, 2003; 139(5_Part_1): 352 - 358. [Full Text] [PDF]

				M.A. Pappolla, T.K. Bryant-Thomas, D. Herbert, J. Pacheco, M. Fabra Garcia, M. Manjon, X. Girones, T.L. Henry, E. Matsubara, D. Zambon, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology Neurology, July 22, 2003; 61(2): 199 - 205. [Abstract] [Full Text] [PDF]

				J. R. Senior Healthy Ranges for Alanine Aminotransferase Levels Ann Intern Med, January 21, 2003; 138(2): 156 - 156. [Full Text] [PDF]

				F. G. De Rosa, S. Bonora, and G. Di Perri Healthy Ranges for Alanine Aminotransferase Levels Ann Intern Med, January 21, 2003; 138(2): 156 - 157. [Full Text] [PDF]

				M. M. Kaplan Alanine Aminotransferase Levels: What's Normal? Ann Intern Med, July 2, 2002; 137(1): 49 - 51. [Full Text] [PDF]